A little more than a year ago, I wrote the story of a cancer drug developed by a tiny company called Loxo Oncology. The medicine only helped patients whose cancer was driven by a particular ...

LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS ...

Eli Lilly and Co. announced Monday it will acquire Loxo Oncology for about $8 billion in cash. The move signals a major push into the cancer drug industry for the global pharmaceutical company ...

A new drug, LOXO-292, targeted this genetic defect. And it made Crouse's cancer shrink. “I feel better now than I have in a long time,” Crouse says. She can go to the grocery store instead of ...

Shares of Loxo Oncology Inc. rallied 34% in premarket trade Monday, after the company said its larotrectinib cancer drug succeeded in shrinking tumors in patients with a variety of cancers that ...

A biotech company called Loxo Oncology won a first-of-its-kind approval from the Food and Drug Administration on Monday, bringing to market a cancer drug that can treat an array of tumors ...

Loxo Oncology Inc (NASDAQ:LOXO), a pharmaceuticals, biotechnology and life sciences company based in United States, View our latest analysis for Loxo Oncology Great news for investors – LOXO is ...

Eli Lilly LLY3.50%increase; green up pointing triangle & Co. said it is buying Loxo Oncology Inc. for $8 billion in cash, a deal that expands the biopharmaceutical company’s oncology-treatment ...

Loxo Oncology Inc. announced one of the biggest such deals of the year Tuesday. For a stake in two Loxo cancer drugs, Bayer AG has agreed to pay $400 million up front and possibly $1 billion or ...

Loxo Oncology has reported encouraging data from a phase 1 trial of RET inhibitor LOXO-292 in solid tumor patients. The drug shrunk the tumors of most patients in the trial, raising hopes it can ...

Loxo Oncology Inc (NASDAQ:LOXO), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. With many analysts ...

Redx Pharma has sold its BTK inhibitor program to Loxo Oncology for $40 million (€34 million) upfront to pay off an outstanding loan. The deal was put together by the insolvency firm Liverpool ...